JPMorgan Assigns Overweight Rating to Immunocore

Immunocore (NASDAQ:IMCR) has received an 'overweight' rating from analysts at JPMorgan Chase & Co., who also set a price target of $50.00 on the stock.

This indicates a potential upside of 38.16% from the company's previous close, according to MarketBeat.

Several other research firms have weighed in on Immunocore, including Weiss Ratings, which reissued a 'sell (e+)' rating, and Mizuho, which upped its price target to $35.00 while giving the company a 'neutral' rating.